Retatrutide is a new pharmaceutical in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By boosting these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimately results in significant slimming. While further invest